Literature DB >> 21725051

Splenic marginal zone lymphoma with VH1-02 gene rearrangement expresses poly- and self-reactive antibodies with similar reactivity.

Abdirashid A Warsame1, Hans-Christian Aasheim, Kjell Nustad, Gunhild Trøen, Anne Tierens, Vivian Wang, Ulla Randen, Hiep P Dong, Sverre Heim, Andreas Brech, Jan Delabie.   

Abstract

One-third of all splenic marginal zone lymphomas (SMZL) use the IgH VH1-02 gene. These cases are usually not associated with hepatitis C virus infection. Of interest, the rearranged VH1-02 genes display similar complementarity determining regions 3, a finding confirmed by our study. The latter suggests that these SMZL may produce antibodies with similar reactivity. We produced recombinant antibodies from 5 SMZL cases with VH1-02 gene rearrangement to study the binding reactivity of these antibodies. Surprisingly, the recombinant antibodies demonstrated poly- and self-reactivity as demonstrated by their reactivity with nuclear, cytoplasmic, as well as membranous antigens expressed by human cells and by reactivity with human serum. This polyreactivity was specific as demonstrated by ELISA. The antibodies did not react with proteins on the cell surface that are induced by apoptosis as shown for antibodies produced by chronic lymphatic leukemia with VH1-02 gene rearrangement. The results indicate that a common subset of SMZL arises from polyreactive B cells, a subset of marginal zone B cells that are important in the immunologic defense against infection.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21725051     DOI: 10.1182/blood-2011-03-341651

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  19 in total

Review 1.  Targeting the B cell receptor pathway in non-Hodgkin lymphoma.

Authors:  Kelly Valla; Christopher R Flowers; Jean L Koff
Journal:  Expert Opin Investig Drugs       Date:  2018-06-07       Impact factor: 6.206

2.  Toll-like receptor stimulation in splenic marginal zone lymphoma can modulate cell signaling, activation and proliferation.

Authors:  Eleonora Fonte; Andreas Agathangelidis; Daniele Reverberi; Stavroula Ntoufa; Lydia Scarfò; Pamela Ranghetti; Giovanna Cutrona; Alessandra Tedeschi; Aliki Xochelli; Federico Caligaris-Cappio; Maurilio Ponzoni; Chrysoula Belessi; Zadie Davis; Miguel A Piris; David Oscier; Paolo Ghia; Kostas Stamatopoulos; Marta Muzio
Journal:  Haematologica       Date:  2015-08-20       Impact factor: 9.941

3.  IgM peak independently predicts treatment-free survival in chronic lymphocytic leukemia and correlates with accumulation of adverse oncogenetic events.

Authors:  D Rizzo; J Chauzeix; F Trimoreau; J B Woillard; F Genevieve; A Bouvier; J Labrousse; C Poli; E Guerin; N Dmytruk; L Remenieras; J Feuillard; N Gachard
Journal:  Leukemia       Date:  2014-06-19       Impact factor: 11.528

4.  A restricted IGHV gene repertoire in splenic marginal zone lymphoma is associated with autoimmune disorders.

Authors:  Gabriel Brisou; Aurélie Verney; Thomas Wenner; Lucile Baseggio; Pascale Felman; Evelyne Callet-Bauchu; Bertrand Coiffier; Françoise Berger; Gilles Salles; Alexandra Traverse-Glehen
Journal:  Haematologica       Date:  2014-07-04       Impact factor: 9.941

Review 5.  Human poly- and cross-reactive anti-viral antibodies and their impact on protection and pathology.

Authors:  Lucile Warter; Ramapraba Appanna; Katja Fink
Journal:  Immunol Res       Date:  2012-09       Impact factor: 2.829

6.  Expressed antibody repertoires in human cord blood cells: 454 sequencing and IMGT/HighV-QUEST analysis of germline gene usage, junctional diversity, and somatic mutations.

Authors:  Ponraj Prabakaran; Weizao Chen; Maria G Singarayan; Claudia C Stewart; Emily Streaker; Yang Feng; Dimiter S Dimitrov
Journal:  Immunogenetics       Date:  2011-12-27       Impact factor: 2.846

7.  Self-antigen recognition by follicular lymphoma B-cell receptors.

Authors:  Kacey L Sachen; Michael J Strohman; Jonathan Singletary; Ash A Alizadeh; Nicole H Kattah; Chen Lossos; Elizabeth D Mellins; Shoshana Levy; Ronald Levy
Journal:  Blood       Date:  2012-09-28       Impact factor: 22.113

Review 8.  Effective management strategies for patients with marginal zone lymphoma.

Authors:  Cecilia B Rosand; Kelly Valla; Christopher R Flowers; Jean L Koff
Journal:  Future Oncol       Date:  2017-12-20       Impact factor: 3.404

9.  Chlamydophila psittaci-negative ocular adnexal marginal zone lymphomas express self polyreactive B-cell receptors.

Authors:  D Zhu; S Bhatt; X Lu; F Guo; H Veelken; D K Hsu; F-T Liu; S Alvarez Cubela; K Kunkalla; F Vega; J R Chapman-Fredricks; I S Lossos
Journal:  Leukemia       Date:  2015-02-13       Impact factor: 11.528

10.  Mouse marginal zone B cells harbor specificities similar to human broadly neutralizing HIV antibodies.

Authors:  Lindsey M Pujanauski; Edward N Janoff; Martin D McCarter; Roberta Pelanda; Raul M Torres
Journal:  Proc Natl Acad Sci U S A       Date:  2013-01-03       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.